Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab Impact on Renal Function in Diabetic Patients
NCT06929507Recruiting
- Sponsor
- University General Hospital of Alexandroupolis
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of faricimab in diabetic macular edema (DME), neovascular age-related macular degeneration (NVAMD) and retinal vein occlusion with macular edema (2 arms), sponsored by University General Hospital of Alexandroupolis. Primary endpoints: Estimated Glomerular Filtration Rate at 12 months and Urine Albumin to Urine Creatinine Ratio at 12 months. Started Mar 2025; status: recruiting.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)retinal vein occlusion with macular edema
Beyond the preview
Go deeper on NCT06929507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929507.